What does USINA PHARM do?

USINA PHARM is a metalworking company in Quévy. Private Limited, started on 20 June 2014, 1 establishment.

What is the address of USINA PHARM?

The registered office of USINA PHARM is located at Rue des Carrières(HAV) 15, 7041 Quévy.

Is USINA PHARM still active?

Yes. According to the CBE (30 October 2026) USINA PHARM is active, legal situation “Normale toestand”, started on 20 June 2014.

Is USINA PHARM registered on Peppol?

Yes, USINA PHARM is registered on the Peppol network with ID 0208:0553961456.

What is the enterprise number of USINA PHARM?

The enterprise number of USINA PHARM is BE0553961456.

When was USINA PHARM founded?

USINA PHARM was founded on 20 June 2014.

Who are the directors of USINA PHARM?

According to the 2025 annual accounts, the directors of USINA PHARM are: CELINE BRUNI, BENJAMIN VANHERREWEGHEN.

Is USINA PHARM a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 June 2014; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did USINA PHARM make in 2025?

USINA PHARM posted a profit after taxes of € 349,643 in financial year 2025.

What is the revenue of USINA PHARM?

As a small company, USINA PHARM is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 783,452.

How much does an employee at USINA PHARM earn?

The average wage cost per full-time employee at USINA PHARM was € 61,700 in 2025: staff costs of € 80,163 for 1.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does USINA PHARM have?

According to the 2025 annual accounts, USINA PHARM has 1.3 full-time equivalents (FTE).

USINA PHARM (Private Limited) - Quévy - BE0553961456

Dossier USINA PHARM, printed on 30 October 2026 from databakkes.be/en/0553961456/usina-pharm. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

USINA PHARM from Quévy, company number BE0553961456, closed financial year 2025 with a result of € 349,643 after tax. For that financial year USINA PHARM recorded a gross margin of € 783,452 and equity of € 2 million. Compared with financial year 2024, the result moved from € 240,555 to € 349,643. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 27, 2026.

What it is worth Growing

€ 2 million

▲ 27% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 349,643

▲ 45% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 789,789

▼ 25% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.9 million.

People and assets in 2025

Full-time equivalents

1.3

▼ 1.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 80,163

▼ 38% vs 2024

€ 61,700 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 30,877

▲ 4% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 7 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 768,665

▼ 13% vs 2024

€ 112,079 is repaid this year. At this pace the long-term loan is gone in ≈ 7 years.

Owed to suppliers

€ 47,623

▼ 55% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 159,972

▲ 4% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 644,741 Gross margin 2022: € 644,741 First fiscal year in the series	€ 772,239 Gross margin 2023: € 772,239 ▲ 20% vs 2022 (€ 644,741) Favourable step	€ 713,847 Gross margin 2024: € 713,847 ▼ 8% vs 2023 (€ 772,239) Unfavourable step	€ 783,452 Gross margin 2025: € 783,452 ▲ 10% vs 2024 (€ 713,847) Favourable step	▲ 10%
Profit after taxes	€ 315,555 Profit after taxes 2022: € 315,555 First fiscal year in the series	€ 289,130 Profit after taxes 2023: € 289,130 ▼ 8% vs 2022 (€ 315,555) Unfavourable step	€ 240,555 Profit after taxes 2024: € 240,555 ▼ 17% vs 2023 (€ 289,130) Unfavourable step	€ 349,643 Profit after taxes 2025: € 349,643 ▲ 45% vs 2024 (€ 240,555) Favourable step	▲ 45%
Equity	€ 1,277,206 Equity 2022: € 1,277,206 First fiscal year in the series	€ 1,344,697 Equity 2023: € 1,344,697 ▲ 5% vs 2022 (€ 1,277,206) Favourable step	€ 1,584,627 Equity 2024: € 1,584,627 ▲ 18% vs 2023 (€ 1,344,697) Favourable step	€ 2,013,688 Equity 2025: € 2,013,688 ▲ 27% vs 2024 (€ 1,584,627) Favourable step	▲ 27%
Total debts	€ 1,726,111 Total debts 2022: € 1,726,111 First fiscal year in the series	€ 1,522,666 Total debts 2023: € 1,522,666 ▼ 12% vs 2022 (€ 1,726,111) Favourable step	€ 1,384,344 Total debts 2024: € 1,384,344 ▼ 9% vs 2023 (€ 1,522,666) Favourable step	€ 1,205,796 Total debts 2025: € 1,205,796 ▼ 13% vs 2024 (€ 1,384,344) Favourable step	▼ 13%
Cash	€ 826,362 Cash 2022: € 826,362 First fiscal year in the series	€ 708,273 Cash 2023: € 708,273 ▼ 14% vs 2022 (€ 826,362) Unfavourable step	€ 1,053,007 Cash 2024: € 1,053,007 ▲ 49% vs 2023 (€ 708,273) Favourable step	€ 789,789 Cash 2025: € 789,789 ▼ 25% vs 2024 (€ 1,053,007) Unfavourable step	▼ 25%
Land & buildings	€ 1,234,898 Land & buildings 2022: € 1,234,898 First fiscal year in the series	€ 1,246,309 Land & buildings 2023: € 1,246,309 ▲ 1% vs 2022 (€ 1,234,898) Unchanged	€ 1,203,664 Land & buildings 2024: € 1,203,664 ▼ 3% vs 2023 (€ 1,246,309) Unchanged	€ 1,146,690 Land & buildings 2025: € 1,146,690 ▼ 5% vs 2024 (€ 1,203,664) Unchanged	▼ 5%
Retained profit	€ 1,254,009 Retained profit 2022: € 1,254,009 First fiscal year in the series	€ 1,324,677 Retained profit 2023: € 1,324,677 ▲ 6% vs 2022 (€ 1,254,009) Favourable step	€ 1,565,232 Retained profit 2024: € 1,565,232 ▲ 18% vs 2023 (€ 1,324,677) Favourable step	€ 1,914,875 Retained profit 2025: € 1,914,875 ▲ 22% vs 2024 (€ 1,565,232) Favourable step	▲ 22%
Dividend	€ 141,370 Dividend 2022: € 141,370 First fiscal year in the series	€ 218,462 Dividend 2023: € 218,462 ▲ 55% vs 2022 (€ 141,370) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 218,462) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 1,043,842 Bank debt 2022: € 1,043,842 First fiscal year in the series	€ 988,461 Bank debt 2023: € 988,461 ▼ 5% vs 2022 (€ 1,043,842) Favourable step	€ 879,281 Bank debt 2024: € 879,281 ▼ 11% vs 2023 (€ 988,461) Favourable step	€ 768,665 Bank debt 2025: € 768,665 ▼ 13% vs 2024 (€ 879,281) Favourable step	▼ 13%
Balance sheet total	€ 3,003,317 Balance sheet total 2022: € 3,003,317 First fiscal year in the series	€ 2,867,363 Balance sheet total 2023: € 2,867,363 ▼ 5% vs 2022 (€ 3,003,317) Unchanged	€ 2,968,971 Balance sheet total 2024: € 2,968,971 ▲ 4% vs 2023 (€ 2,867,363) Unchanged	€ 3,219,484 Balance sheet total 2025: € 3,219,484 ▲ 8% vs 2024 (€ 2,968,971) Unchanged	▲ 8%
Employees (FTE)	2 Employees (FTE) 2022: 2 First fiscal year in the series	2.4 Employees (FTE) 2023: 2.4 ▲ 0.4 vs 2022 (2) Unchanged	2.4 Employees (FTE) 2024: 2.4 Unchanged (2.4) Unchanged	1.3 Employees (FTE) 2025: 1.3 ▼ 1.1 vs 2024 (2.4) Unchanged	▼ 1.1

Key figures of USINA PHARM, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to USINA PHARM?

What happened at USINA PHARM in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 27, 2026 New annual accounts for financial year 2025: profit of € 349,643 (▲ 45% vs 2024). filed late Source: NBB ↗
Jul 1, 2014 New establishment in Frameries. KBO
Jun 20, 2014 Start of the company according to the CBE. KBO

In short

From € 315,555 profit in 2022 to € 349,643 profit in 2025.

Paid € 468,168 in corporate taxes since 2022.

Best year ever: 2025, with € 349,643 profit.

On average € 602,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

CELINE BRUNI BENJAMIN VANHERREWEGHEN

USINA PHARM

Behind USINA PHARM are CELINE BRUNI and BENJAMIN VANHERREWEGHEN.

Directors

According to the 2025 annual accounts

CELINE BRUNI

Director

BENJAMIN VANHERREWEGHEN

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Rue des Carrières(HAV) 15

7041 Quévy

2.231.871.515

Av.du Parc d'Avent.Scientifiques 3 box 2

7080 Frameries

Active since 1 July 2014

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0553.961.456

VAT number

BE 0553.961.456

Registered office

Rue des Carrières(HAV) 15, 7041 Quévy

Names & denominations

USINA PHARM

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

20 June 2014

Peppol

Active · Active since 20 Nov 2020

Activities · NACE

Verspanend bewerken van metalen

Vervaardiging van verlichtingsapparaten

View on CBE Public ↗ Annual accounts (NBB) ↗

USINA PHARM

Financials

What happened to USINA PHARM?

Management

Directors

Establishments

Establishment units

Details

Frequently asked questions